PMH49 ESTIMATING ANNUAL US PREVALENCE OF SCHIZOPHRENIA IN 2002  by Wu, EQ et al.
399Abstracts
lation 0.81). Test-retest reliability was also high for all items of
the RDQ (reliability coefﬁcient > 0.9) and the readiness for dis-
charge status (tetrachoric correlation 0.82). Overall, 84% of the
raters agreed that the RDQ was useful in assessing patients’
readiness for discharge. Evidence of good construct validity
included signiﬁcant correlations with PANSS total and factor
scores, and a signiﬁcant relationship with actual discharge. Sig-
niﬁcantly more patients with symptom improvement were
judged ready for discharge (compared to those without symptom
improvement), indicating that the RDQ was responsive to
change over time. CONCLUSIONS: The RDQ has favorable
reliability and validity properties, and is an easy to use instru-
ment for assessing readiness for discharge of inpatients with
schizophrenia. The RDQ can be a useful tool in research settings,
as it provides a measure of the effects of an intervention on dis-
charge, independent of socio-economic inﬂuences.
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OBJECTIVES: The use of concomitant antipsychotics and other
psychotropics and the costs of polypharmacy in patients ran-
domized to risperidone or quetiapine were examined in a
prospective double-blind study. METHODS: Subjects were
patients with an acute exacerbation of schizophrenia or schizoaf-
fective disorder. In a 14-day phase, patients were randomized to
risperidone, quetiapine, or placebo monotherapy. In the follow-
ing 28-day additive-therapy phase, clinicians were allowed to
add antipsychotics or other psychotropics (including antidepres-
sants, anxiolytics, mood stabilizers and sedative/hypnotics).
Doses of risperidone or quetiapine were ﬁxed in the additive
therapy phase. RESULTS: Mean (±SD) doses at monotherapy
endpoint were 4.7 ± 0.9mg/day of risperidone and 579.5 ± 128.9
mg/day of quetiapine. Among 133 patients randomized to
risperidone, 33% received additional antipsychotics and 36%
received one or more psychotropics (including antipsychotics).
In the quetiapine group (N = 122), 53% and 53% received addi-
tional antipsychotics or psychotropics, respectively (P < 0.005 vs.
risperidone in both). In the placebo group, 57% received antipsy-
chotics and 62% psychotropics. The relative risk (quetiapine vs.
risperidone) for antipsychotic polypharmacy was 1.90 (95% CI
1.29–2.80). Improvements in PANSS total scores were signiﬁ-
cantly greater in patients receiving risperidone than quetiapine
or placebo at monotherapy endpoint (P < 0.001) and signiﬁ-
cantly greater with risperidone than placebo at the additive-
therapy endpoint (P < 0.01); quetiapine–placebo differences were
not signiﬁcant. The mean costs of antipsychotic polypharmacy
(for the duration of the additive-therapy phase) per randomized
patient were $57.03 in the risperidone group and $101.64 in the
quetiapine group (P < 0.05). The costs of the primary antipsy-
chotic plus the additional antipsychotics were $354,339 in the
risperidone group and $524,319 in the quetiapine group. CON-
CLUSIONS: The results conﬁrm earlier observations of higher
rates of polypharmacy with quetiapine than with risperidone.
These ﬁndings suggest that differential costs associated with
polypharmacy can be substantial.
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OBJECTIVE: This study aims to conduct a systematic review on
the literature concerning relapse and non-adherence in schizo-
phrenia patients in eight countries (Australia, Canada, France,
Germany, Italy, Spain, UK, and US). METHODS: As of Sep-
tember, 2004, a literature search was performed in a number of
databases including MEDLINE (1966–2004), EMBASE
(1980–2004), PsycINFO (1967–2004), Cumulative Index to
Nursing and Allied Health Literature (1980–2004) and other
health technology assessment databases. Of the 1000 retrieved
articles, around half were eventually reviewed in full text.
RESULTS: Although deﬁnitions and measures of adherence and
relapse between studies were very diverse, the rate of relapse in
schizophrenia appeared to be from 40% to 55% for patients not
taking the medication, and 14% to 30% for stabilized patients
maintained on medication. Conventional antipsychotics tended
to have higher rates of relapse than atypical antipsychotics. Most
relapses tended to occur within the ﬁrst year and, as such, many
studies had a short follow-up period. The medication adherence
rate for patients with schizophrenia ranged from 20% to 90%.
This review has found that adherence is affected by environ-
mental factors (e.g. social support), medication factors (e.g. side
effects or lack of efﬁcacy), doctor-patient relationship (e.g. lack
of knowledge concerning the illness), forgetfulness, and treat-
ment factors (e.g. medication regimes that are too complex).
There was substantial evidence that depot medication aids
patient adherence. Because current depot medications are avail-
able for conventional antipsychotics and risperidone, it was sug-
gested that considerable advantages may be observed when more
atypical antipsychotics are used in depot form. CONCLUSION:
Relapse and non-adherence to antipsychotic agents in schizo-
phrenia patients are quite prevalent and associated with adverse
consequences. Furthermore, because treatment adherence
appears to be strongly linked with relapse in schizophrenia, it is
important that treatment interventions continue to address the
problem of medication non-adherence.
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OBJECTIVES: This study estimates the 2002 annual prevalence
of schizophrenia in the US based on administrative claims data
analyses and a comprehensive literature review. METHODS:
The population-speciﬁc annual prevalence rates of schizophrenia
in the US were estimated separately for privately insured, gov-
ernment insured (Medicare, Medicaid), and uninsured popula-
tions. The 2002 annual prevalence for privately insured
individuals was calculated based on a de-identiﬁed administra-
tive claims database of approximately 3.0 million privately
insured beneﬁciaries covering the period from 1999 to 2003. 
The 2002 prevalence of Medicaid enrollees was calculated 
from Medi-Cal claims covering the period from 2000–2002. The
2002 schizophrenia prevalence in Medicare population was cal-
culated as a weighted average of the prevalence rates of Medic-
aid/Medicare dual eligibles and private insurance program
enrollees over 65. Published statistics were used to estimate the
prevalence of schizophrenia in the uninsured population. Finally,
400 Abstracts
prevalence rates in different populations were weighted to esti-
mate the 2002 annual schizophrenia prevalence in the general
US population. RESULTS: The annual prevalence rate of schiz-
ophrenia in the US in 2002 was estimated at 0.5%. The Medic-
aid population was identiﬁed as having the highest schizophrenia
prevalence rate in the US (1.7% for non-Medicare dual eligible
enrollees), whereas annual schizophrenia prevalence rates in
Medicare and privately insured population were 0.7% and
0.1%, respectively. The disease was also more prevalent in the
uninsured population (1.1%). CONCLUSIONS: The results
suggest that schizophrenia may be more prevalent in the US
general population than previously estimated in some epidemi-
ology survey studies, especially given the fact that claims data-
base analyses usually provide lower bounds of prevalence
estimates. Schizophrenia is most prevalent in the low income and
uninsured populations than in the privately insured or Medicare
populations. Given the high cost of the disease, efforts should be
made to reach patients in these populations to deliver appropri-
ate treatments.
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OBJECTIVE: To investigate the impact of inpatient versus out-
patient treatment of schizophrenia on psychiatric hospital pro-
ﬁtability in Japan. This is a timely investigation because one of
the Japanese Government’s current objectives is to shift treat-
ment of schizophrenic patients from the inpatient to the outpa-
tient setting. METHODS: The investigators accessed schedules
of hospital reimbursement in Japan and met with a group of
Japanese private hospital owners to gain a sound understanding
of costs and income of private psychiatric hospitals. An interac-
tive model was then built which allowed quantiﬁcation and sim-
ulation of proﬁtability of inpatient versus outpatient treatment.
The model will be supplied to hospital owners in Japan so that
they can assess the proﬁtability of different treatment settings for
their hospital. RESULTS: The preliminary analysis using the
model found that revenues were higher if patients were treated
in the inpatient setting, compared with the outpatient setting. In
a typical hospital, approximately 21–24 outpatients are required
to generate a similar income to that earned from treatment of
one inpatient. In order to achieve this, hospitals would be
required to expand their outpatient care capacity and improve
the quality of outpatient care. CONCLUSIONS: Shifting the
treatment of patients from the inpatient to the outpatient setting
will require a signiﬁcant expansion of the current outpatient care
capacity. Further improvement in the quality of outpatient care
will be necessary to attract more patients to compensate for the
revenue loss associated with the shift. The project demonstrates
the complexities of undertaking ﬁnancial analysis in Japan.
While it is possible to conduct such projects, researchers need to
explore a range of data options and consult widely with the
intended user.
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OBJECTIVES: To assess the cost-effectiveness of long-acting
risperidone (LAI-RIS), oral risperidone (RIS), olanzapine (OLA),
quetiapine (QUE), ziprasidone (ZIP), aripiprazole (ARI), and
haloperidol decanoate (HAL-DEC) in patients with schizophre-
nia over one-year from a health care system perspective.
METHODS: Published medical literature, an unpublished con-
sumer health database, and a clinical expert panel were utilized
to populate a decision tree model. The model captured rates of
compliance and relapse, frequency and duration of relapse,
adverse events, resource utilization and unit costs. Outcomes
included percentage, number and duration of relapses per patient
per year and direct medical costs. RESULTS: The mean days of
relapse requiring hospitalization per patient per year were 28
HAL-DEC, 18 RIS, OLA, QUE, ZIP and ARI, 11 LAI-RIS, while
the mean days of exacerbation not requiring hospitalization were
eight HAL-DEC, ﬁve RIS, OLA, QUE, ZIP and ARI, three LAI-
RIS. Direct medical cost savings with LAI-RIS compared to RIS,
OLA, QUE, ZIP, ARI, and HAL-DEC were $161, $1425, $508,
$259, $1068, and $8224, respectively. CONCLUSIONS: Long-
acting risperidone may lead to substantially lower rates and
fewer days of symptom exacerbation and hospitalization com-
pared to currently available treatments. These lower rates trans-
late into direct medical cost savings with the use of long-acting
risperidone.
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OBJECTIVES: To compare the direct annual mental health 
cost and the cost of service components for schizophrenia
patients who relapsed with patients who did not relapse.
METHODS: Data were drawn from a large multi-site three-
year prospective naturalistic study of patients treated for schiz-
ophrenia in the United States, conducted between July, 1997 
and September, 2003. Relapse was deﬁned as psychiatric 
hospitalization, use of emergency services, use of crisis beds, or
suicide attempts. Relapse-related and other service utilization
was based on patients’ medical records and patients’ self-reports,
collected at enrollment and at six-month intervals thereafter.
Costs (charges) were based on the treatment sites’ medical 
information systems. Propensity score adjusted bootstrap re-
sampling was used to compare the total one-year mental 
health cost and cost of service components for patients who
relapsed with those who did not relapse. RESULTS: Patients 
who relapsed (20%, or N = 310/1557) incurred signiﬁcantly
higher mental health cost during the following one-year as com-
pared to patients who did not relapse ($33,296 vs. $11,823 p <
0.01). In addition to higher cost of acute care services (e.g., psy-
chiatric hospitalizations and emergency services), the relapsed
patients also had signiﬁcantly higher cost of day treatment
($1816 vs. $1510, p < 0.01), medication management ($1436
vs. $1125, p < 0.01), outpatient individual therapy ($1987 vs.
$1088, p < 0.01), and case management ($1406 vs. $907, p <
0.01). The cost of all psychotropic medications was numerically
but not statistically higher ($5646 vs. $4611, n.s), reﬂecting 
a numerically higher cost of antipsychotics ($4313 vs. $3636,
n.s), and of other psychotropic agents ($1333 vs. $976, n.s).
CONCLUSIONS: Relapse of patients with schizophrenia is 
associated with substantial direct mental health costs. Findings
highlight the economic impact of relapse and the importance 
